Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: Role of didanosine

Antiviral Therapy

Volumn 15, Issue 5, 2010, Pages 753-763

  Merchante, Nicolás ^a   Pérez Camacho, Inés ^b   Mira, José A ^a   Rivero, Antonio ^b   Macías, Juan ^a   Camacho, Ángela ^b   Gómez Mateos, Jesús ^a   García Lázaro, Milagros ^b   Torre Cisneros, Julián ^b   Pineda, Juan A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; ZALCITABINE; ZIDOVUDINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; ELASTOGRAPHY; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIVER INJURY; LIVER TOXICITY; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RIGIDITY; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DIDANOSINE; ELASTICITY; ELASTICITY IMAGING TECHNIQUES; FEMALE; HIV INFECTIONS; HUMANS; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TIME FACTORS;

EID: 77957326331     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1612     Document Type: Article

References (45)

1. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
2. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355:1158-1159.
3. Pineda JA, García-García JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-630.
4. The Data Collection on Adverse Events of Anti-HIV Drugs Study Group. Liver-related deaths in persons infected with HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
5. Bica I, McGovern B, Dhaz R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32:492-497.
6. Rosenthal E, Poirée M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17:1803-1809.
7. Maida I, Núñez M, Rios MJ, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-182.
8. Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103-107.
9. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis is a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536-2540. (Pubitemid 47631766)
10. Mallet V, Blanchard P, Verkarre V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187-192. (Pubitemid 46036926)
11. Garvey LJ, Thomson EC, Lloyd J, Cooke GS, Goldin RD, Main J. Response to Mallet, et al. 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'. AIDS 2007; 21:1494-1495.
12. Castera L, Vergniol J, Fouvher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350. (Pubitemid 40439195)
13. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
14. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29:242-247.
15. Corpechot C, El Naggar A, Poujol-Robert A, et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43:1118-1124.
16. Yoneda M, Fujita K, Inamori M, Nakajima A, Tamamo M, Hiraishi H. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56:1330-1331. (Pubitemid 47300449)
17. Ganne-Carrié N, Ziol M, de Ledinghen V, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44:1511-1517. (Pubitemid 44953656)
18. de Lédinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/Hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
19. Vergara S, Macías J, Rivero A, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45:969-974.
20. Macías J, Recio E, Vispo E, et al. Application of transient elastometry to differentiate mild from moderate to severe liver fibrosis in HIV/HCV co-infected patients. J Hepatol 2008; 49:916-922.
21. Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45:1290-1297.
22. Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12:1791-1798.
23. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847.
24. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
25. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11:787-797.
26. Benhamou Y, Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-287. (Pubitemid 32702341)
27. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52:1035-1040. (Pubitemid 36765298)
28. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10:118-125. (Pubitemid 36359849)
29. Martín-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-133. (Pubitemid 38045883)
30. Macías J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18:767-774. (Pubitemid 38535004)
31. Mariné-Barjoan E, Saint-Paul M-C, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18:2163-2170.
32. Macías J, Mira JA, López-Cortés LF, et al. Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C. Antivir Ther 2006; 11:839-846.
33. Lin W, Weinberg EM, Tai AW, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008; 134:803-811. (Pubitemid 351312737)
34. Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49:626-635.
35. Daniel F, Cadranel J, Seksik P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol 2005; 29:600-603.
36. De Bruyne R, Portmann B, Samyn M, et al. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol 2006; 44:407-410.
37. Vora A, Mitchell C, Lennard L, et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 2006; 368:1339-1348. (Pubitemid 44528747)
38. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-1426.
39. The SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
40. Lang S, Mary-Krause M, Cotte L, et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 43LB.
41. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51:20-28.
42. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 721.
43. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evolution of liver fibrosis in patients with chronic liver disease. Gut 2007; 56:968-973. (Pubitemid 46999083)
44. Neukam K, Recio E, Camacho A, et al. Interobserver concordance in the assessment of liver fibrosis in HIV/HCV-coinfected patients using transient elastometry. Eur J Gastroenterol Hepatol 2010; 22:801-807.
45. Roulot D, Czernichow S, Le Clésiau H, Costes J-L, Vergnaud A-C, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48:606-613.